Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Trovagene
Sort By
Newest First
1 / 1
1 / 1
Oncology
Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC)
Trovagene
PR-M01-19-NI-089
Jan 31, 2019
Drug Development
Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer
Trovagene
PR-M01-19-NI-073
Jan 25, 2019
Financial Results
Trovagene Announces Third Quarter 2018 Highlights and Financial Results
Trovagene
PR-M11-18-NI-037
Nov 12, 2018
Clinical Trial
Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial
Trovagene
PR-M09-18-NI-061
Sep 20, 2018
Approval
Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075
Trovagene
PR-M09-18-NI-048
Sep 18, 2018
Orphan Drug
Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene's Investigational Cancer Drug
Trovagene
PR-M08-18-NI-032
Aug 09, 2018
